biologics

Comparison of Cross-linked and Non-Cross-linked Acellular Porcine Dermal Scaffolds for Long-term Full-Thickness Hernia Repair in a Small Animal Model

03/27/2021

Pavel Vesely , MD, PhD;

Veronika Hromadkova , MD;

Jakob Miletin , MD;

Robert Juzek , MD;

Jan Mestak , MD, PhD;

Martin Molitor , MD, PhD;

Andrej Sukop , MD, PhD;

Ondrej Mestak , MD;

Zuzana Spurkova , MD;

Kamila Benkova , MD;

Comparison of Cross-linked and NonCross-linked Acellular Porcine Dermal Scaffolds for Long-term Full-Thickness Hernia Repair in a Small Animal Model Ondrej Mestak, MD,a Zuzana Spurkova, MD,b Kamila Benkova, MD,b Pavel Vesely, MD,...

Comparison of Cross-linked...

03/27/2021

ePlasty

Research Reports

Implications of Manufacturer Contracting: A Quantitative Model to Assess Biosimilar Market Feasibility

10/15/2018

Michael Kuehn , RPh;

Jay Galli ;

Abstract: Eight years have passed since Congress enacted the Biologics Price Competition and Innovation Act (BPCIA) of 2010. Since then, 12 biosimilars have received approval from the Food and Drug Administration,...

...

10/15/2018

Journal of Clinical Pathways

Perspectives

Formulary Decisions and the Evolution of Psoriasis Treatment

12/14/2015

Steven R. Feldman , MD, PhD;

William Malatestinic , PharmD, MBA;

David Amato , MD;

Abstract: Psoriasis is a common and significant illness characterized by systemic inflammation. In its mildest form, psoriasis can often be managed with relatively low-cost topical therapies; but for...

...

12/14/2015

Journal of Clinical Pathways